Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm

被引:8
|
作者
Nishino, Mizuki [1 ,2 ]
Wakai, Satoshi [3 ]
Hida, Tomoyuki [1 ,2 ]
Dahlberg, Suzanne E. [4 ]
Ozaki, Masahiro [3 ]
Hatabu, Hiroto [1 ,2 ]
Tachizaki, Hisashi [3 ]
Johnson, Bruce E. [5 ,6 ,7 ]
机构
[1] Brigham & Womens Hosp, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[3] Canon Med Syst Corp, 1385 Shimoishigami, Otawara, Tochigi 3248550, Japan
[4] Dana Farber Canc Inst, Dept Biostat, 450 Brookline Ave, Boston, MA 02215 USA
[5] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
[6] Dana Farber Canc Inst, Dept Med, 450 Brookline Ave, Boston, MA 02215 USA
[7] Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
Lung cancer; Epidermal growth factor receptor; EGFR inhibitor; Computed tomography; Tumor growth rate; DIFFERENT TREATMENT MODALITIES; RESPONSE EVALUATION CRITERIA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; NSCLC PATIENTS; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; GEFITINIB; PROGRESSION;
D O I
10.1016/j.ejrad.2018.10.014
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To develop an automated analytic module for calculation of tumor growth rate from serial CT scans and to apply the module and evaluate reproducibility in a pilot cohort of advanced NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors. Materials and methods: The module utilized a commercially available image-processing workstation equipped with a validated tumor volume measurement tool. An automated analytic software module was programmed with the capability to record and display serial tumor volume changes and to calculate tumor volume growth rate over time and added to the workstation. The module was applied to evaluate the tumor growth rate in a pilot cohort of 24 EGFR-mutant patients treated with EGFR inhibitors, and reproducibility references as tested by two independent thoracic radiologists. Results: The module analyzed chest CT scans from 24 patients (5 males, 19 females; median age: 61) with a median of 8 scans per patient, totaling 227 scans and provided a graphical display with an automated and instant calculation of tumor growth rate after the nadir volume for each patient. High inter and intraobserver agreements were noted for tumor growth rates, with concordance correlation coefficients of 0.9323 and 0.9668, respectively. Interpretation of slow versus fast tumor growth using previously identified threshold of <= 0.15/month had a perfect interobserver agreement (kappa = 1.00), and an excellent intraobserver agreement (kappa = 0.895). Conclusions: The present study describes the development of an image analytic module for assessing tumor growth rate and the data demonstrates the functionality and reproducibility of the module in a pilot cohort of EGFR-mutant NSCLC patients treated with EGFR-TKI. The image analytic module is an initial step for clinical translation of the tumor growth rate approach to guide cancer treatment in precision oncology.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 50 条
  • [21] Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer
    Chang, John Wen-Cheng
    Chou, Chun-Liang
    Huang, Shiu-Feng
    Wang, Hung-Ming
    Hsieh, Jia-Juan
    Hsu, Todd
    Cheung, Yun-Chung
    LUNG CANCER, 2007, 58 (03) : 414 - 417
  • [22] The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (41) : 71358 - 71370
  • [23] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [24] Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with EGFR TKI
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Cardarella, Stephanie
    Jackman, David M.
    Rabin, Michael S.
    Hatabu, Hiroto
    Jaenne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : 1059 - 1068
  • [25] A differential analysis of TCR repertoire between patients with EGFR-mutant and KRAS-mutant non-small-cell lung cancer
    Xie, Yuancai
    Li, Yingmei
    Dong, Linfeng
    Chen, Shifu
    Liu, Jixian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer
    Liu, Si-Yang
    Zhang, Jia-Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 217 - +
  • [27] Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer-ready for prime time?
    Arulananda, Surein
    John, Thomas
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 1728 - 1731
  • [28] FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer
    Gold, Kathryn A.
    Erasmus, Jeremy J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) : 1131 - 1132
  • [29] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
    Zhang, Hongye
    Wang, Ruiyu
    Wang, Mingxia
    Luo, Judong
    Liu, Changmin
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
  • [30] Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
    Wang, Haiyang
    Yu, Xiaoqing
    Fan, Yun
    Jiang, Youhua
    ONCOTARGETS AND THERAPY, 2018, 11 : 2149 - 2155